Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 May 16:27:e00221.
doi: 10.1016/j.crwh.2020.e00221. eCollection 2020 Jul.

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Jonathon Anderson  1 , Jordan Schauer  1 , Suzanne Bryant  1 , Cornelia R Graves  1
Affiliations
Case Reports

The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report

Jonathon Anderson et al. Case Rep Womens Health. .

Abstract

Remdesivir is a novel therapeutic with known activity against SARS CoV-2 and related coronaviruses. Remdesivir, as well as convalescent plasma therapy, are currently under investigation as potential therapies for patients with Coronavirus Disease 19 (COVID-19). In this case report we summarize the use of convalescent plasma therapy and then remdesivir as a late addition in the treatment of a critically ill obstetric patient with COVID-19. The patient subsequently improved, was extubated 5 days after initiation of remdesivir, was transitioned to room air 24 h later, and discharged at the completion of remdesivir therapy.

Keywords: COVID-19; Convalescent plasma; Coronavirus; Pregnancy; Remdesivir; SARS CoV-2.

PubMed Disclaimer

References

    1. Dashraath P., Wong J.L.J., Lim M.X.K. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy. Am. J. Obstet. Gynecol. 2020 in press. - PMC - PubMed
    1. Kochhar D.M., Penner J.D., Knudsen T.B. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol. Appl. Pharmacol. 1980;52(1):99–112. - PubMed
    1. Winthrop K.L. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat. Rev. Rheumatol. 2017;13(4):234–243. - PubMed
    1. Tchesnokov E.P., Feng J.Y., Porter D.P., Götte M. Mechanism of inhibition of ebola virus RNA-dependent RNA polymerase by Remdesivir. Viruses. 2019;11:326. - PMC - PubMed
    1. Gordon C.J., Tchesnokov E.P., Feng J.Y., Porter D.P., Gotte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem. 2020;295:4773–4779. - PMC - PubMed

Publication types